Arbutus Biopharma Corporation Common Stock
Here’s whether Arbutus Biopharma Corporation Common Stock (ABUS) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+1.83% over 10 days); strong 1-year return of +45.5%; 3-month momentum positive (+19.8%); rising volume confirms the move (1.58x 30d avg). Concerns: RSI 75 — overbought, elevated pullback risk. Currently 4.4% off its 52-week high. Score: +6/7.
ABUS is in a confirmed uptrend, trading above both its 50-day ($4.61) and 200-day ($4.46) moving averages. With an RSI of 75.2, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +45.5% compares to +20.5% for SPY (beat the market by 25.1%).